THERAPY DOSSIER · th-c747a0958e1b

Adenosine, lidocaine and magnesium (ALM) resuscitation fluid

Procedure

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29554045 ↗2018Reported benefit

Adenosine, lidocaine, and Mg2+ (ALM) resuscitation fluid protects against experimental traumatic brain injury.

RatTBIFluid percussionSprague-DawleyMalen = 16 per group across four groups, with a subdural cerebral b…IntravenousSingle 3% NaCl with or without ALM bolus of 0.7 mL/kg intra…Bolus given 15 minutes after injury

Model: Moderate lateral fluid-percussion traumatic brain injury at 2.57 atm in anaesthetised, mechanically ventilated rats

ALM eliminated mortality (0% versus 25% in saline controls), increased cortical blood flow roughly threefold at 60 minutes, improved left ventricular function, lowered pro-inflammatory cytokines and brain injury markers and reduced coagulopathy.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…